Deerfield Management’s Amicus Therapeutics FOLD Stock Holding History

Deerfield Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-21,723	Closed	-$232K	–	231
2024 Q3	$232K	Sell	21,723 -8,029	-27%	-$87.4K	﹤0.01%	409
2024 Q2	$295K	Buy	29,752 +13,263	+80%	+$136K	﹤0.01%	346
2024 Q1	$194K	Buy	+16,489	New	+$211K	﹤0.01%	337
2021 Q3	–	Sell	-2,941,492	Closed	-$28.4M	–	141
2021 Q2	$28.4M	Buy	2,941,492 +242,995	+9%	+$2.37M	0.5%	64
2021 Q1	$26.7M	Buy	+2,698,497	New	+$41.8M	0.56%	60
2020 Q3	–	Sell	-1,416,000	Closed	-$21.4M	–	108
2020 Q2	$21.4M	Sell	1,416,000 -1,837,960	-56%	-$22.4M	0.62%	53
2020 Q1	$30.1M	Buy	+3,253,960	New	+$30.9M	0.95%	33
2014 Q4	–	Sell	-480,000	Closed	-$2.86M	–	118
2014 Q3	$2.86M	Buy	+480,000	New	+$2.51M	0.1%	107

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deerfield Management's FOLD Position: Q4 2024 in Review

Deerfield Management sold out of Amicus Therapeutics (FOLD) in Q4 2024, closing a stake of 21,723 shares — an estimated $232K sold.

Deerfield Management first reported a position in FOLD in Q3 2014 and held it in 8 quarters. The position peaked at $30.1M in Q1 2020. 290 funds tracked by Wall St. Rank hold FOLD as of Q4 2024.

Deerfield Management reported no remaining Amicus Therapeutics position as of Q4 2024 after selling out during the quarter.
Deerfield Management sold 21,723 Amicus Therapeutics shares in Q4 2024, an estimated $232K.
Deerfield Management first reported a position in Amicus Therapeutics in Q3 2014 and held it in 8 quarters.
Deerfield Management's Amicus Therapeutics position peaked at $30.1M in Q1 2020.
290 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2024.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.